This clinical trial aims to investigate the effects of Transcranial Magnetic Stimulation (TMS) as an adjunctive treatment for young adult patients with depression and non-suicidal self-injury (NSSI). The main questions this study aims to answer are: * Does adjunctive TMS reduce psychiatric symptoms in young adults with major depressive disorder and non-suicidal self-injury? * Does adjunctive TMS cause any changes in neuroimaging markers in young adults with major depressive disorder and non-suicidal self-injury? * Does adjunctive TMS cause any effects on blood biomarkers in young adults with major depressive disorder and non-suicidal self-injury? Participants in this study will undergo an extensive clinical evaluation, functional neuroimaging tests (MRI and fNIRS), and peripheral blood collection. They will be randomly assigned to one of two interventions: (1) 20 sessions of TMS using the intermittent theta burst stimulation (iTBS) protocol, or (2) 20 sham sessions using a placebo procedure with the TMS equipment. After the 20 sessions, additional clinical assessments, neuroimaging and blood tests will be conducted. The data analysis will compare the two groups in terms of response and remission of internalizing and externalizing psychiatric symptoms, as well as neuroimaging and blood tests outcomes.
This comprehensive clinical trial seeks to explore the potential therapeutic benefits of Transcranial Magnetic Stimulation (TMS) when used as an adjunctive treatment for young adult patients grappling with both depression and non-suicidal self-injury (NSSI). The overarching objectives of this study are multifaceted and aim to address critical questions regarding the efficacy and underlying mechanisms of TMS in this particular demographic. The primary research inquiries guiding this investigation are: Psychiatric Symptom Reduction: Does the incorporation of adjunctive TMS lead to a significant reduction in psychiatric symptoms among young adults diagnosed with major depressive disorder and non-suicidal self-injury? Neuroimaging Markers: Does adjunctive TMS induce any discernible changes in neuroimaging markers among young adults with major depressive disorder and non-suicidal self-injury? This involves employing sophisticated functional neuroimaging techniques such as MRI (Magnetic Resonance Imaging) and fNIRS (functional Near-Infrared Spectroscopy). Blood Biomarkers: Are there observable effects on blood biomarkers in young adults with major depressive disorder and non-suicidal self-injury following adjunctive TMS treatment? To investigate these questions, participants enrolled in the study will undergo an extensive and thorough clinical evaluation. Additionally, functional neuroimaging tests, encompassing both MRI and fNIRS, will be administered to gain insights into the neural correlates of TMS treatment. Furthermore, peripheral blood samples will be collected to analyze potential changes in blood biomarkers associated with TMS. The study design incorporates a randomized assignment of participants to one of two interventions: Active TMS Intervention: Participants will undergo 20 sessions of TMS utilizing the intermittent theta burst stimulation (iTBS) protocol. Sham TMS Intervention: A control group will receive 20 sham sessions involving a placebo procedure with the TMS equipment. Following the completion of the intervention phase, participants will undergo additional clinical assessments, neuroimaging, and blood tests to comprehensively evaluate the impact of TMS treatment. The subsequent data analysis will involve a rigorous comparison of the two groups, assessing factors such as the response and remission of internalizing and externalizing psychiatric symptoms, as well as outcomes related to neuroimaging and blood tests.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
40
The Intermittent Theta Burst Stimulation (iTBS) protocol will be used. This protocol involves bursts of stimulation at the theta frequency range, approximately 5 to 8 Hz. The specific combination utilized combines bursts of pulses at a frequency of 50 Hz, triggered at a rate of 5 Hz. Thus, a burst of 3 pulses is delivered with intervals of 20 ms between them, and this burst is repeated at intervals of 200 ms (i.e., 5 bursts per second). Every second, 15 pulses are delivered.
A stimulator with an arm containing a non-functional replica of the stimulation coil will be utilized. The application procedures will be identical to those of the active group, except that the device simulating the stimulation coil will not generate a magnetic field, only producing sound cues mimicking a stimulus.
Instituto do Cérebro do Rio Grande do Sul
Porto Alegre, Rio Grande do Sul, Brazil
RECRUITINGHamilton Depression Rating Scale
Proportion of individuals with a 50% or more score reduction between before and after intervention
Time frame: Week 1 prior to TMS treatment and week 1 after completion of TMS treatment
Patient Health Questionnaire-9
Proportion of individuals with a 50% or more score reduction between before and after intervention
Time frame: Week 1 prior to TMS treatment and week 1 after completion of TMS treatment
Montgomery-Asberg Depression Rating Scale
Proportion of individuals with a 50% or more score reduction between before and after intervention
Time frame: Week 1 prior to TMS treatment and week 1 after completion of TMS treatment
fMRI assessed neural network connectivity
Change on functional connectivity
Time frame: Week 1 prior to TMS treatment and week 1 after completion of TMS treatment
fMRI-assessed resting connectivity
Change (e.g. normalization) of baseline network-level deficits.
Time frame: Week 1 prior to TMS treatment and week 1 after completion of TMS treatment
Functional Assessment of Self-Mutilation (FASM)
Difference in score between before and after the intervention
Time frame: Week 1 prior to TMS treatment and week 1 after completion of TMS treatment
Hamilton Depression Rating Scale
Proportion of individuals with a 50% or more score reduction between before and after intervention
Time frame: 1, 3 , 6 and 12 months after completion of TMS treatment
Patient Health Questionnaire-9
Proportion of individuals with a 50% or more score reduction between before and after intervention
Time frame: 1, 3 , 6 and 12 months after completion of TMS treatment
Montgomery-Asberg Depression Rating Scale
Proportion of individuals with a 50% or more score reduction between before and after intervention
Time frame: 1, 3 , 6 and 12 months after completion of TMS treatment
fNIRS- assessed changes in blood oxygenation levels in the brain
Changes in blood oxygenation levels in the brain measured by fNIRS (functional near-infrared spectroscopy) to infer neural activity
Time frame: Week 1 prior to TMS treatment and week 1 after completion of TMS treatment
Brain-Derived Neurotrophic Factor (BDNF)
Changes in BDNF levels comparing pre- and post-treatment
Time frame: Week 1 prior to TMS treatment and week 1 after completion of TMS treatment
Ciliary Neurotrophic Factor (CNTF)
Changes in CNTF levels comparing pre- and post-treatment
Time frame: Week 1 prior to TMS treatment and week 1 after completion of TMS treatment
Glial Cell-Derived Neurotrophic Factor (GDNF)
Changes in GDNF levels comparing pre- and post-treatment
Time frame: Week 1 prior to TMS treatment and week 1 after completion of TMS treatment
Nerve Growth Factor (NGF)
Changes in GDNF levels comparing pre- and post-treatment
Time frame: Week 1 prior to TMS treatment and week 1 after completion of TMS treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.